Intensive Study Nurse Training

Dr Florescu Moraid earned her Medical Doctor degree in 1998 from the Carol Davila University of Medicine and Pharmacy in Bucharest. She was accredited as a Laboratory Medicine Specialist in 2005 and as a Senior Laboratory Medicine Specialist in 2011 by the Romanian College of Physicians.

She completed a Master of Science degree in 2006, the Postgraduate School of Clinical Trials Management in Gdańsk in 2012, and the Postgraduate Leadership Development Programme at the University of Sussex in 2014.

Between 2005 and 2018, Dr Florescu Moraid led clinical trial operations at Synevo Central Lab, the clinical research division of the Swedish Medicover Group, serving as Regional Director for Romania, Moldova, Bulgaria, and Serbia. During this period, she also organised the Synevo Clinical Trials Symposium for ten consecutive years.

Since 2019, she has been the Co-founder of Avantyo - Institute of Clinical Research and the CEO of Camina Medical Experts, providing tailored clinical trial services to pharmaceutical sponsors, CROs, and mid-sized biotech companies.

She is a frequent invited speaker at scientific meetings and a committed advocate for strengthening awareness of the value of clinical trials for patients.

Dr Delia Codruța Popa earned her Doctor of Medicine degree in 2015 from the Carol Davila University of Medicine and Pharmacy in Bucharest, with a doctoral thesis entitled Evaluation of circulating HCV genotypes in Romania. She is a Primary Physician in Laboratory Medicine and the Coordinator of the Haematological Analysis Laboratory at the Fundeni Clinical Institute in Bucharest. She also serves as Head of Work at the Department of Biochemistry of the Carol Davila University of Medicine and Pharmacy.

Her academic and research activity includes participation in a wide range of national and European programmes. These include CEEX 158/2006 (2006–2008), investigating molecular mechanisms within the HCV genome; the SUNFLOWER project (2008–2010) under the European Commission Public Health Programme, focused on innovative HIV prevention strategies for young people; and the H-CUBE project (2009–2011), addressing HBV, HCV, and HIV as major public health challenges for European youth. She also contributed to PNII‑PD23/2011 (2011–2013), evaluating hepatic transcription factor expression in hepatocarcinoma, and PNII‑PCE 125/2011 (2011–2016), studying molecular predictors of prognosis following curative treatment of hepatocellular carcinoma.

Her more recent work includes serving as Project Director for the PNIII Mobility Project (2017) and contributing to the HEPATER management training programme (2018–2022), supporting Romanian medical personnel caring for patients chronically infected with hepatitis B and C viruses. Dr Popa is the author or co‑author of 16 ISI‑indexed articles and more than 60 scientific papers presented at national and international conferences.

• March 2021–present: Head of Laboratory, Ponderas Hospital, CMU, Bucharest
• September 2015–March 2021: Medical Director of Medcenter Laboratories, Romania
• August 2013–August 2015: Medical Director, CBC Laboratories Romania
• July 2009–August 2015: primary physician in laboratory medicine, Head of laboratory at CBC Laboratories, Cord Blood Center, Bucharest
• May 2008–June 2009: Primary Physician Laboratory Medicine, Head of Laboratory, S.C. Puls Medica SRL, Bucharest
• March 2005–April 2008: primary physician laboratory medicine; microbiology department coordinator: S.C. Synevo Romania SRL, Bucharest
• February 2000–February 2005: laboratory medicine specialist; microbiology department coordinator; S.C. Medicover Rombel SRL, Bucharest
• February 1998–January 2000: residency in microbiology (bacteriology, parasitology, virology, and immunology) at the Cantacuzino Institute in Bucharest
• February 1997–January 1998: residency in biochemistry at Fundeni Clinical Institute in Bucharest
• February 1996–January 1997: residency in hematology at Coltea Clinical Hospital, Bucharest

Dr Loredana Patru is a dedicated medical doctor specialising in Clinical Pharmacology. She graduated from the prestigious Carol Davila University of Medicine and Pharmacy in Bucharest, Romania, in 2007. Since then, her career has been defined by commitment, professionalism and a genuine desire to improve patients lives. She qualified as a Clinical Pharmacology specialist in 2012 and became a senior specialist in 2017.

With more than 15 years experience as an investigator in clinical trials, Dr Patru has been closely involved in pioneering Phase 1 and Phase 2 studies, exploring innovative therapies across a broad range of disease areas, including multi-therapeutic approaches and oncology. Her work is guided by a strong belief in scientific rigour, patient safety and operational excellence. She is dedicated to ensuring that every protocol is carried out to the highest standard, always keeping patients well-being at the forefront, and she collaborates closely with forward-thinking pharmaceutical companies and external partners to achieve shared objectives.

In 2025, drawing on her extensive clinical research expertise and her deep commitment to patient care, Dr Patru founded the association Elion. The initiative was born from her desire to empower patients and increase awareness of clinical studies within their communities. In this role, she actively supports efforts to improve access to reliable information, fostering collaborations that advance medical research and ultimately help transform lives.